Serum CEO Adar Poonawalla 'delighted' as Oxford's COVID-19 vaccine shows over 70% efficacy

Serum Institute of India CEO ar Poonawalla said on vember 23 that he is “delighted” to kw Oxford University’s COVID-19 vaccine candidate developed with AstraZeneca has shown efficacy up to 90 per cent. After Oxford me anuncement on Monday of its vaccine candidate being 90% and 62% efficient in two different s of doss, making entire efficacy over 70%, Poonawalla took to Twitter to welcome ‘low-cost’ and easy to store vaccine. 

While more details are awaited by end of vember 23, Poonawalla has alrey said last week that Oxford COVID-19 vaccine should be available for healthcare workers and elderly people by around February next year and by April for general citizens.

Re - India Could Get Oxford Covid Vaccine By Feb 2021; Rs 1000 For 2 Doses: Serum's Poonawalla

In latest “important milestone” in world’s fight against pandemic, Oxford University has anunced on vember 23 that its COVID-19 vaccine candidate developed in collaboration with AstraZeneca is 70.4% effective against highly-infectious disease. It is both a triumph but also a matter of disappointment because Pfizer-BioNTech and Moderna have alrey declared ir respective vaccine candidates to be 95% and 94% efficient against COVID-19. However, Oxford and AstraZeneca’s vaccine is reportedly far cheaper and is comparatively easier to store and transport to even remote areas of world. 

Re - Oxford's COVID-19 Vaccine Shows Over 70% Efficacy As India Looks To Give Emergency Use d

Oxford COVID-19 vaccine’s efficacy in two doses

Anuncing interim trial data from its Phase 3 trials, Oxford University said in a statement that its vaccine candidate ChOx1 nCoV-2019 has shown more than 70 per cent efficacy after analysis included 131 COVID-19 cases. Testing in two different test regimes, vaccine was 90% efficient in one and 62% efficient in ar. According to statement, “higher efficacy regimen used a halved first dose and standard second dose.” Easier to refrigerate, Oxford-AstraZeneca’s COVID-19 vaccine will play a significant role in tackling global health crisis. 

‘ anuncement today takes us ar step closer to time when we can use vaccines to bring an end to devastation caused by SARS-CoV-2. We will continue to work to provide detailed information to regulators. It has been a privilege to be part of this multi-national effort which will reap benefits for whole world,” said vaccine's architect Professor Sarah Gilbert.

Re - 25,000 Health Workers Identified In Meghalaya For First Batch Of COVID-19 Vaccine

Re - Hancock Welcomes Oxford University Vaccine News